E-mail lunthesis@163.com Phone 0551-65179860-203

China greenlights new COVID-19 vaccine candidate for human trials

Pub Date:2020-06-28 09:08 Source:Xinhua

Chinese authorities have approved a new COVID-19 vaccine candidate for human trials, the Institute of Microbiology under the Chinese Academy of Sciences, said in a statement.

The recombinant protein vaccine was issued with a clinical research permit from the National Medical Products Administration on June 19, according to the institute, which is the vaccine's main developer.

Researchers will start phase-1 clinical trials in hospitals in Chongqing and Beijing, to determine whether the vaccine is safe for use on humans, its co-developer Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. confirmed.

It represents the third type of COVID-19 vaccine developed by Chinese researchers to enter clinical trials. One adenovirus vaccine and four inactivated vaccines have previously been approved for human tests in China, with some having just cleared phase-2 trials. 


Editor:Rita

Related News
- China greenlights new COVID-19 vaccine candidate for huma...    2020-06-28 09:08
- China launches human trials for new COVID-19 vaccine    2020-06-24 16:40
- Anhui,Zhejiang and Jiangsu to realize trans-provincial m...    2020-06-23 09:31
- Project of Anhui hospital affiliated to Children’s hospi...    2020-06-18 15:26
 
photo  >>
Hefei-Huzhou section of Shangqiu-Hefei-Hangzhou High-speed Railway opens
Hefei: a comfortable habitat for egrets
Video  >>
(AmazingAnhui)She inkstone, a national cultural heritage in E China's Anhui
(AmazingAnhui)Huizhou inkstick, a cultural heritage in E China's Anhui
People  >>
Poor farmer in East China's Anhui becomes poultry expert
Datong barbers are a cut above competition
Travel  >>
Chinese people make over 78m trips during Dragon Boat Festival holiday
Shangqiu-Hefei-Hangzhou rail likely to open to traffic on June 28
Contact Us
Copyright ©2000-2016 anhuinews.com All rights reserved. Reproduction in whole or in part without permission is prohibited.